JCR Pharma, The Current Fiscal Year Ordinary Profit Revised Downward by 84%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Jan 31, 2025 4:00 pm JST Earnings

4552 JCR Pharmaceuticals Co.,Ltd. 【J-GAAP】

Earnings Report

JCR Pharmaceuticals Co.,Ltd. <4552> [TSE Prime] announced its financial results after the market closed on January 31st (16:00). The consolidated ordinary profit/loss for the cumulative third quarter of the fiscal year ending March 2025 (April to December) turned into a loss of 1.38 billion yen (compared to a profit of 7.38 billion yen in the same period last year).

In addition, the full-year consolidated ordinary profit has decreased 83.7%, from the previous forecast of 4.6 billion yen to 0.75 billion yen (compared to 7.26 billion yen in the previous period), leading to an increase in the profit decline rate from 36.7% to 89.7%.

Based on the full-year plan announced by the company after the downward revision, our estimate of the consolidated ordinary profit for the October to March period (2H) has decreased 61.9%, from the previous forecast of 6.22 billion yen to 2.37 billion yen (compared to 0.13 billion yen in the same period of the previous year), leading to a reduction in the profit growth rate from 45 times to 17 times.

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit decreased to 0.24 billion yen, a 8.0% decrease compared to the same period last year. The operating profit/loss margin drastically worsened from 9.6% in the same period last year to -0.2%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	26,696	4,953	5,291	3,568	28.7	97.7	Jan 31, 2023	J-GAAP
Apr - Dec, 2023	33,718	7,809	7,388	5,160	41.4	101.7	Jan 26, 2024	J-GAAP
Apr - Dec, 2024	25,880	-754	-1,380	-576	-4.6	ー	Jan 31, 2025	J-GAAP
YoY	-23.2%	－	－	－	－

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	24,643	6,139	6,221	4,391	36.0	10	Oct 30, 2024	J-GAAP
Oct - Mar, 2024 New	22,343	2,139	2,371	2,891	23.7	10	Jan 31, 2025	J-GAAP
Revision Rate	-9.3%	-65.2%	-61.9%	-34.2%	-34.2%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	41,300	5,400	4,600	3,700	30.4	20	May 10, 2024	J-GAAP
Mar, 2025 New	39,000	1,400	750	2,200	18.1	20	Jan 31, 2025	J-GAAP
Revision Rate	-5.6%	-74.1%	-83.7%	-40.5%	-40.5%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	18,599	633	138	254	2.0	10	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	22,343	2,139	2,371	2,891	23.7	10	Jan 31, 2025	J-GAAP
YoY	+20.1%	+237.9%	+1,618.1%	+1,038.2%	+1,063.2%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	34,343	4,975	5,418	3,772	30.4	20	May 11, 2023	J-GAAP
Mar, 2024	42,871	7,531	7,264	5,507	44.1	20	May 10, 2024	J-GAAP
Mar, 2025 Guidance	39,000	1,400	750	2,200	18.1	20	Jan 31, 2025	J-GAAP
YoY	-9.0%	-81.4%	-89.7%	-60.1%	-59.1%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	9,446	911	262	-93	-0.8	9.6	Jan 26, 2024	J-GAAP
Jan - Mar, 2024	9,153	-278	-124	347	2.8	-3.0	May 10, 2024	J-GAAP
Apr - Jun, 2024	8,145	-296	-257	201	1.6	-3.6	Jul 30, 2024	J-GAAP
Jul - Sep, 2024	8,512	-443	-1,364	-892	-7.1	-5.2	Oct 30, 2024	J-GAAP
Oct - Dec, 2024	9,223	-15	241	115	0.9	-0.2	Jan 31, 2025	J-GAAP
YoY	-2.4%	－	-8.0%	－	－